$VTGN News Article - Vistagen Announces Results of Successful U.S. Phase 1 Study of Itruvone (PH10), Enabling U.S. Phase 2B Development for Treatment of Major Depressive Disorder https://marketwirenews.com/news-releases/vist...42354.html
(0)
(0)
VistaGen Therapeutics, Inc. (VTGN) Stock Research Links